This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Jiang, Z.-D.
Right arrow Articles by Dupont, H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Jiang, Z.-D.
Right arrow Articles by Dupont, H.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Medline Plus Health Information
*Bowel Movement
*E. Coli Infections

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, August 2000, p. 2205-2206, Vol. 44, No. 8
0066-4804/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.

In Vitro Activity and Fecal Concentration of Rifaximin after Oral Administration

Zhi-Dong Jiang,1,* Shi Ke,2 Ernesto Palazzini,3 Lise Riopel,4 and Herbert Dupont1,5

Center for Infectious Disease, School of Public Health and Medical School, University of Texas---Houston,1 University of Texas M.D. Anderson Cancer Center,2 and St. Luke's Episcopal Hospital and Baylor College of Medicine,5 Houston, Texas; Alfa Wassermann, S.p.A. Bologna, Italy3; and Salix Pharmaceuticals Inc., Palo Alto, California4

Received 27 January 2000/Returned for modification 31 March 2000/Accepted 28 April 2000

Rifaximin showed moderately high MICs (the MIC at which 90% of the isolates tested were inhibited = 50 µg/ml) for 145 bacterial enteropathogens from patients with traveler's diarrhea acquired in Mexico during the summers of 1997 and 1998. Rifaximin concentrations in stool the day after oral administration (800 mg daily for 3 days) were high (average, 7,961 µg/g), proving the value of the drug.

* Corresponding author. Mailing address: University of Texas School of Public Health, 1200 Herman Pressler, Room 706, Houston, TX 77030. Phone: (713) 500-9371. Fax: (713) 500-9364. E-mail: ZJIANG{at}UTSPH.SPH.UTH.TMC.EDU.

Antimicrobial Agents and Chemotherapy, August 2000, p. 2205-2206, Vol. 44, No. 8
0066-4804/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.


This article has been cited by other articles:

  • Finegold, S. M., Molitoris, D., Vaisanen, M.-L. (2009). Study of the In Vitro Activities of Rifaximin and Comparator Agents against 536 Anaerobic Intestinal Bacteria from the Perspective of Potential Utility in Pathology Involving Bowel Flora. Antimicrob. Agents Chemother. 53: 281-286 [Abstract] [Full Text]  
  • O'Connor, J. R., Galang, M. A., Sambol, S. P., Hecht, D. W., Vedantam, G., Gerding, D. N., Johnson, S. (2008). Rifampin and Rifaximin Resistance in Clinical Isolates of Clostridium difficile. Antimicrob. Agents Chemother. 52: 2813-2817 [Abstract] [Full Text]  
  • Garey, K. W, Salazar, M., Shah, D., Rodrigue, R., DuPont, H. L (2008). Rifamycin Antibiotics for Treatment of Clostridium difficile-Associated Diarrhea. The Annals of Pharmacotherapy 42: 827-835 [Abstract] [Full Text]  
  • Ruiz, J., Mensa, L., Pons, M. J., Vila, J., Gascon, J. (2008). Development of Escherichia coli rifaximin-resistant mutants: frequency of selection and stability. J Antimicrob Chemother 61: 1016-1019 [Abstract] [Full Text]  
  • Taylor, D. N., McKenzie, R., Durbin, A., Carpenter, C., Haake, R., Bourgeois, A. L. (2008). Systemic Pharmacokinetics of Rifaximin in Volunteers with Shigellosis. Antimicrob. Agents Chemother. 52: 1179-1181 [Abstract] [Full Text]  
  • Ma, X., Shah, Y. M., Guo, G. L., Wang, T., Krausz, K. W., Idle, J. R., Gonzalez, F. J. (2007). Rifaximin Is a Gut-Specific Human Pregnane X Receptor Activator. J. Pharmacol. Exp. Ther. 322: 391-398 [Abstract] [Full Text]  
  • TAYLOR, D. N., BOURGEOIS, A. L., ERICSSON, C. D., STEFFEN, R., JIANG, Z.-D., HALPERN, J., HAAKE, R., DUPONT, H. L., THE RIFAXIMIN STUDY GROUP, (2006). A RANDOMIZED, DOUBLE-BLIND, MULTICENTER STUDY OF RIFAXIMIN COMPARED WITH PLACEBO AND WITH CIPROFLOXACIN IN THE TREATMENT OF TRAVELERS' DIARRHEA. Am J Trop Med Hyg 74: 1060-1066 [Abstract] [Full Text]  
  • DuPont, H. L., Jiang, Z.-D., Okhuysen, P. C., Ericsson, C. D., de la Cabada, F. J., Ke, S., DuPont, M. W., Martinez-Sandoval, F. (2005). A Randomized, Double-Blind, Placebo-Controlled Trial of Rifaximin To Prevent Travelers' Diarrhea. ANN INTERN MED 142: 805-812 [Abstract] [Full Text]  
  • Pakyz, A. L (2005). Rifaximin: A New Treatment for Travelers' Diarrhea. The Annals of Pharmacotherapy 39: 284-289 [Abstract] [Full Text]  
  • Scrascia, M., Forcillo, M., Maimone, F., Pazzani, C. (2003). Susceptibility to rifaximin of Vibrio cholerae strains from different geographical areas. J Antimicrob Chemother 52: 303-305 [Abstract] [Full Text]  
  • Sierra, J. M., Navia, M. M., Vargas, M., Urassa, H., Schellemberg, D., Gascon, J., Vila, J., Ruiz, J. (2001). In vitro activity of rifaximin against bacterial enteropathogens causing diarrhoea in children under 5 years of age in Ifakara, Tanzania. J Antimicrob Chemother 47: 904-905 [Full Text]  
  • Sierra, J. M., Ruiz, J., Navia, M. M., Vargas, M., Gascon, J., Vila, J. (2001). In Vitro Activity of Rifaximin against Enteropathogens Producing Traveler's Diarrhea. Antimicrob. Agents Chemother. 45: 643-644 [Full Text]  
  • Gomi, H., Jiang, Z.-D., Adachi, J. A., Ashley, D., Lowe, B., Verenkar, M. P., Steffen, R., DuPont, H. L. (2001). In Vitro Antimicrobial Susceptibility Testing of Bacterial Enteropathogens Causing Traveler's Diarrhea in Four Geographic Regions. Antimicrob. Agents Chemother. 45: 212-216 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»